Memorial Sloan-Kettering Cancer Center;Yissum Research Development Company of the Hebrew University LTD
发明人:
Richard Kolesnick,Yechezkel Barenholz,Erez Koren
申请号：
US14854891
公开号：
US10052387B2
申请日:
2015.09.15
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Based on the observation that the application of small amounts of exogenous acid sphingomyelinase to generate endogenous ceramide, or provision of exogenous long-chain natural C16-ceramide resulted in rapid translocation of vacuolar daunorubicin into the nucleus in multi-drug resistant (MDR) cells, the present invention relates to a nano-liposomal preparation that includes C16-ceramide. Exposure of MDR cells to the C16:0 ceramide-based nanoliposomes provide a mechanism to reverse MDR in chemoresistant cells and tumors, by inducing rapid translocation of chemotherapeutic agent from cytoplasmic vesicles to the nucleus.
